EGFR and neoplasm: At that time point an additional analysis for KRAS mutational status and EGFR protein expression (which were conducted within a translational research project) detected a wildtype sequence of KRAS exon 2 by pyrosequencing and a moderately positive immunohistochemical staining for membranous EGFR expression in about 80% of the tumor cells.